Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation

Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation: A Single-Center Retrospective Study

This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients at a single high-volume transplant center in Korea.

The study aims to compare overall survival and the incidence of biliary complications.

This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients underwent LDLT between January 2012 and December 2022 at a single high-volume transplant center in Korea. Among them, 121 received ABO-I grafts using a rituximab-based desensitization protocol, while 390 underwent ABO-C LDLT. The study aims to compare overall survival and the incidence of biliary complications, as well as to identify risk factors specific to each group. This analysis provides insights into the long-term safety and efficacy of ABO-I LDLT in regions with low deceased donor organ availability.

Inclusion Criteria:

• All adult patients who underwent LDLT at the study center from 2012 to 2022

Exclusion Criteria:

• Pediatric patients, deceased donor recipients, multi-organ transplants.